Skip to content
sellWeak10b5-1 plan

Marshall Fordyce sold $731k of VERA

PRESIDENT AND CEO at Vera Therapeutics, Inc.. 17,500 shares at an average of $41.74, traded Jan 8, 2025, filed Jan 10, 2025.

Warning score
16
Value
$731k
17,500 shares
Holdings after
143,603
-11% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    CEO
    +25
  • Trade size
    $731k at market
    +21
  • Share of holdings sold
    Sold 11% of holdings
    +5
  • Cluster
    No other insider selling within 14 days
    0
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -2.4%, 3m -39.4%, 6m -35.7%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

VERAOct 12, 2026 · close 27.72
Since filing Jan 10, 2025: -25.1%SPY +36.7% · excess -61.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001415889-25-001242, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jan 8, 2025MOption exercise
Class A Common Stock10b5-1
+9,975$2.90$29k153,578Jan 10, 2025
Jan 8, 2025SOpen-market sale
Class A Common Stock10b5-1
-9,975$41.53$414k143,603Jan 10, 2025
Jan 8, 2025MOption exercise
Class A Common Stock10b5-1
+5,650$2.90$16k149,253Jan 10, 2025
Jan 8, 2025SOpen-market sale
Class A Common Stock10b5-1
-5,650$42.03$237k143,603Jan 10, 2025
Jan 8, 2025MOption exercise
Class A Common Stock10b5-1
+1,875$2.90$5,432145,478Jan 10, 2025
Jan 8, 2025SOpen-market sale
Class A Common Stock10b5-1
-1,875$42.00$79k143,603Jan 10, 2025
Jan 8, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-15,625$0.00$0610,926Jan 10, 2025
Jan 8, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-1,875$0.00$0609,051Jan 10, 2025

Related signals

Other insiders at Vera Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
11Weak
VERAsell10b5-1
Vera Therapeutics, Inc.
Marshall Fordyce
PRESIDENT AND CEO
$685k
18,500 shares
-7%
10Weak
VERAsell10b5-1
Vera Therapeutics, Inc.
Marshall Fordyce
PRESIDENT AND CEO
$650k
18,500 shares
-7%
11Weak
VERAsell10b5-1
Vera Therapeutics, Inc.
Marshall Fordyce
PRESIDENT AND CEO
$680k
18,500 shares
-7%
11Weak
VERAsell10b5-1
Vera Therapeutics, Inc.
Marshall Fordyce
PRESIDENT AND CEO
$702k
18,500 shares
-7%
20Weak
VERAsell10b5-1
Vera Therapeutics, Inc.
Marshall Fordyce
PRESIDENT AND CEO
$2.0M
46,250 shares
-16%
35Weak
VERAsell10b5-1
Vera Therapeutics, Inc.
Marshall Fordyce
PRESIDENT AND CEO
$2.0M
46,250 shares
-23%
26Weak
VERAsell10b5-1
Vera Therapeutics, Inc.
Marshall Fordyce
PRESIDENT AND CEO
$702k
18,500 shares
-9%
26Weak
VERAsell10b5-1
Vera Therapeutics, Inc.
Marshall Fordyce
PRESIDENT AND CEO
$680k
18,500 shares
-8%
30Weak
VERAsell10b5-1
Vera Therapeutics, Inc.
Marshall Fordyce
PRESIDENT AND CEO
$1.0M
22,951 shares
-9%
39Weak
VERAsell 7
Vera Therapeutics, Inc.
Robert Brenner
Chief Medical Officer
$90k
2,151 shares
-4%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Marshall Fordyce sold $731k of VERA | InsiderTell